- Home
- SAGE vs ACTG Comparison
SAGE vs ACTG Comparison
Compare SAGE & ACTG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAGE
- ACTG
- Stock Information
- Founded
- SAGE 2010
- ACTG 1993
- Country
- SAGE United States
- ACTG United States
- Employees
- SAGE N/A
- ACTG N/A
- Industry
- SAGE Biotechnology: Pharmaceutical Preparations
- ACTG Multi-Sector Companies
- Sector
- SAGE Health Care
- ACTG Miscellaneous
- Exchange
- SAGE Nasdaq
- ACTG Nasdaq
- Market Cap
- SAGE 415.0M
- ACTG 289.2M
- IPO Year
- SAGE 2014
- ACTG 1996
- Fundamental
- Price
- SAGE $6.71
- ACTG $3.54
- Analyst Decision
- SAGE Hold
- ACTG
- Analyst Count
- SAGE 19
- ACTG 0
- Target Price
- SAGE $9.88
- ACTG N/A
- AVG Volume (30 Days)
- SAGE 934.8K
- ACTG 300.1K
- Earning Date
- SAGE 04-29-2025
- ACTG 05-08-2025
- Dividend Yield
- SAGE N/A
- ACTG N/A
- EPS Growth
- SAGE N/A
- ACTG N/A
- EPS
- SAGE N/A
- ACTG N/A
- Revenue
- SAGE $47,404,000.00
- ACTG $222,414,000.00
- Revenue This Year
- SAGE $100.64
- ACTG $86.80
- Revenue Next Year
- SAGE $70.19
- ACTG N/A
- P/E Ratio
- SAGE N/A
- ACTG N/A
- Revenue Growth
- SAGE N/A
- ACTG 65.22
- 52 Week Low
- SAGE $4.62
- ACTG $2.70
- 52 Week High
- SAGE $14.56
- ACTG $5.74
- Technical
- Relative Strength Index (RSI)
- SAGE 35.06
- ACTG 66.50
- Support Level
- SAGE $7.23
- ACTG $2.99
- Resistance Level
- SAGE $7.63
- ACTG $3.21
- Average True Range (ATR)
- SAGE 0.29
- ACTG 0.12
- MACD
- SAGE -0.09
- ACTG 0.06
- Stochastic Oscillator
- SAGE 0.38
- ACTG 89.16
About SAGE Sage Therapeutics Inc.
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.
About ACTG Acacia Research Corporation (Acacia Tech)
Acacia Research Corp is focused on acquiring and operating businesses across the industrial, energy, and technology sectors where it believes it can leverage its expertise, capital base, and deep industry relationships to drive value. The company has four reportable business segments: Intellectual Property Operations, Industrial Operations, Energy Operations and Manufacturing Operations. It derives revenue from Intellectual Property Operations segment. Geographically, it operates in Americas, Europe, Middle East and Africa, China, India, and Asia-Pacific, excluding China and India.